Sonata Jodele, MD
- Member, Division of Bone Marrow Transplantation and Immune Deficiency
- Professor, UC Department of Pediatrics
- sonata.jodele@cchmc.org
- Board Certified
About
Biography
I am an internationally recognized expert in every aspect of transplant-associated thrombotic microangiopathy (TMA), working on both clinical and research applications. My work was instrumental in linking TMA pathophysiology to the complement pathway, which demonstrated the relationship of the disease to specific clinical and genetic factors. Then, I established a new paradigm for therapy with inhibition of the complement pathway.
My ongoing research aims to develop new and better therapies for TMA. Currently, I lead multi-disciplinary international collaborative groups and research projects with clinicians and scientists from Germany, Switzerland, Italy and Japan. I also serve as a clinical consultant for physicians throughout the world regarding care of complex patients with TMA.
In previous work, I led the first prospective TMA biomarker and genetic predisposition studies. My efforts resulted in practical applications for clinical care, as well as comprehensive diagnostic laboratory panels now offered for patients worldwide. I also proposed new diagnostic algorithms and risk stratification data for TMA to help guide timely therapy initiation.
Additionally, I piloted ground-breaking complement blocking therapeutic agents for hematopoietic stem cell transplantation (HSCT) recipients living with severe TMA while also describing unique drug pharmacokinetics in this patient population. As a result of this work, the first prospective early intervention clinical study opened at four major United States pediatric healthcare centers. The study evaluates eculizumab for stem cell transplant recipients with high risk TMA.
My continuing research is supported by the National Institutes of Health (NIH) as well as institutional and industry-sponsored grants.
MD: Vilnius University School of Medicine, Vilnius, Lithuania, 1988-1994.
Residency: Pediatrics, SUNY Health Science Center at Brooklyn, Brooklyn, NY, 1998-2001.
Fellowship: Pediatric Hematology/Oncology, Children's Hospital Los Angeles and Saban Research Institute, Keck School of Medicine University of Southern California, Los Angeles, CA, 2001-2004.
Certifications: Pediatrics, 2001; Pediatric Hematology / Oncology, 2004.
Licenses: California, 2001-present; Ohio, 2004-present.
Interests
Bone marrow transplantation and cellular therapies
Services and Specialties
Bone Marrow Transplantation BMT, Cancer and Blood Diseases
Interests
Thrombotic microangiopathies; organ toxicity prevention in transplant patients
Research Areas
Bone Marrow Transplantation and Immune Deficiency
Publications
Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020; 135:1049-1057.
Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Advances. 2020; 4:1166-1177.
High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Bone Marrow Transplantation. 2018; 53:1311-1318.
Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination. Transplantation and Cellular Therapy. 2016; 22:1337-1340.
New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfusion and Apheresis Science. 2016; 54:181-190.
The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2016; 127:989-996.
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 2016; 22:307-315.
Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation and Cellular Therapy. 2014; 20:518-525.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey